Mitochondrial dysfunction in obesity: Potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome

被引：55
作者：
Alam M.A. [1 ,2 ]
Rahman M.M. [2 ]
机构：
[1] School of Biomedical Science, The University of Queensland, Brisbane
[2] Department of Pharmaceutical Sciences, North South University, Dhaka
来源：
Journal of Diabetes & Metabolic Disorders | / 13卷 / 1期
关键词：
Co-enzyme Q10; Inflammation; Metabolic syndrome; Obesity; Oxidative stress;
D O I：
10.1186/2251-6581-13-60
中图分类号：
学科分类号：
摘要：
Co-enzyme Q10 (Co-Q10) is an essential component of the mitochondrial electron transport chain. Most cells are sensitive to co-enzyme Q10 (Co-Q10) deficiency. This deficiency has been implicated in several clinical disorders such as heart failure, hypertension, Parkinson's disease and obesity. The lipid lowering drug statin inhibits conversion of HMG-CoA to mevalonate and lowers plasma Co-Q10 concentrations. However, supplementation with Co-Q10 improves the pathophysiological condition of statin therapy. Recent evidence suggests that Co-Q10 supplementation may be useful for the treatment of obesity, oxidative stress and the inflammatory process in metabolic syndrome. The anti-inflammatory response and lipid metabolizing effect of Co-Q10 is probably mediated by transcriptional regulation of inflammation and lipid metabolism. This paper reviews the evidence showing beneficial role of Co-Q10 supplementation and its potential mechanism of action on contributing factors of metabolic and cardiovascular complications. © 2014 Alam and Rahman; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 147 条
[81]  
Flock M.R., Green M.H., Kris-Etherton P.M., Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol, Advances in Nutrition, 2, pp. 261-274, (2011)
[82]  
Henninger D.D., Gerritsen M.E., Granger D.N., Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli, Cir Res, 81, pp. 274-281, (1997)
[83]  
Zabalawi M., Bhat S., Loughlin T., Thomas M.J., Alexander E., Cline M., Bullock B., Willingham M., Sorci-Thomas M.G., Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol, Am J Pathol, 163, pp. 1201-1213, (2003)
[84]  
Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K., Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J Clin Invest, 106, pp. 523-531, (2000)
[85]  
Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K., The peroxisome proliferator-activated receptor-[gamma] is a negative regulator of macrophage activation, Nature, 391, pp. 79-82, (1998)
[86]  
Cuzzocrea S., Mazzon E., Di Paola R., Peli A., Bonato A., Britti D., Genovese T., Muia C., Crisafulli C., Caputi A.P., The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation, J Leukoc Biol, 79, pp. 999-1010, (2006)
[87]  
Schmelzer C., Lorenz G., Rimbach G., Doring F., In vitro effects of the reduced form of coenzyme Q10 on secretion levels of TNF-α and chemokines in response to LPS in the human monocytic cell line THP-1, J Nutr Biochem, 44, pp. 62-66, (2009)
[88]  
Schmelzer C., Lorenz G., Rimbach G., Doring F., Influence of Coenzyme Q10 on release of pro-inflammatory chemokines in the human monocytic cell line THP-1, BioFactors, 31, pp. 211-217, (2007)
[89]  
Carmona M.C., Lefebvre P., Lefebvre B., Galinier A., Benani A., Jeanson Y., Louche K., Flajollet S., Ktorza A., Dacquet C., Penicaud L., Casteilla L., Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice, Int J Obes, 33, pp. 204-211, (2009)
[90]  
Sohet F.M., Neyrinck A.M., Pachikian B.D., de Backer F.C., Bindels L.B., Niklowitz P., Menke T., Cani P.D., Delzenne N.M., Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice, Biochem Pharmacol, 78, pp. 1391-1400, (2009)
45678910111213